Neurodegenerative diseases endure a great challenge, being regarded as a significant cause of morbidity and mortality in the elderly, with no cure to date. The progressive degeneration of neurons sends an alarm toward the benefit of early identification and the discovery of agents capable of ceasing the progression. Non-coding RNA, DNA methylation, and histone modifications are examples of epigenetics which are implicated as potential clinical biomarkers in the pathogenesis of neurodegenerative diseases. Nutrition-based therapy, or nutraceuticals, have recently gained importance owing to their multifaceted effects, suggesting that they hypothetically attenuate the progression of neuronal damage. These food-based approaches are believed to target multiple pathways and non-coding RNA in neurodegenerative diseases without causing severe adverse effects. Understanding the mechanistic role of these food-based drugs may help to develop novel therapeutic options during neurodegeneration. The impact of polymorphism on the progression and response to nutraceuticals in clinical studies is also within the addressed scope.
Aging is a natural phenomenon that can affect the normal brain in various ways, leading to physiological and behavioral problems. Furthermore, the aging process has been linked to the occurrence and advance of neurodegenerative diseases in aged people. Thus, the aim of the current Research Topic is to provide promising, and novel research trends on the experimental and clinical use of nutraceuticals in neurodegenerative diseases, including Alzheimer’s disease, Parkinson's disease, Huntington's disease, Multiple sclerosis, and Amyotrophic lateral sclerosis (ALS), with special emphasis on the role of epigenetics, non-coding RNA in neural plasticity as well as pharmacogenomics on treatment response.
We welcome submissions in the form of original research articles, review articles, literature reviews, mini-reviews, systematic reviews, or case studies that cover the following (but are not limited to) topics:
•Novel molecular targets in the diagnosis, pathogenesis, and progression of neurodegenerative diseases, which include:
-Mitochondrial dysfunction
-Endoplasmic reticulum-stress pathways
-Mitotoxicity, oxidative stress, and inflammation
•Epigenetics, including non-coding RNA expression patterns and profiling in neurodegenerative diseases.
•Translational research of nutraceuticals mechanism of action in neurodegenerative diseases.
•Clinical studies using nutraceuticals in neurodegenerative diseases.
•Immunotherapies in neurodegenerative diseases.
•Types of food-based nutraceuticals (Nutrients, minerals, fatty acids, vitamins, and amino acids).
•Probiotics and microbiome-brain crosstalk in neurodegenerative diseases.
•Impact of Polymorphism on progression and response to nutraceuticals in clinical studies.
Neurodegenerative diseases endure a great challenge, being regarded as a significant cause of morbidity and mortality in the elderly, with no cure to date. The progressive degeneration of neurons sends an alarm toward the benefit of early identification and the discovery of agents capable of ceasing the progression. Non-coding RNA, DNA methylation, and histone modifications are examples of epigenetics which are implicated as potential clinical biomarkers in the pathogenesis of neurodegenerative diseases. Nutrition-based therapy, or nutraceuticals, have recently gained importance owing to their multifaceted effects, suggesting that they hypothetically attenuate the progression of neuronal damage. These food-based approaches are believed to target multiple pathways and non-coding RNA in neurodegenerative diseases without causing severe adverse effects. Understanding the mechanistic role of these food-based drugs may help to develop novel therapeutic options during neurodegeneration. The impact of polymorphism on the progression and response to nutraceuticals in clinical studies is also within the addressed scope.
Aging is a natural phenomenon that can affect the normal brain in various ways, leading to physiological and behavioral problems. Furthermore, the aging process has been linked to the occurrence and advance of neurodegenerative diseases in aged people. Thus, the aim of the current Research Topic is to provide promising, and novel research trends on the experimental and clinical use of nutraceuticals in neurodegenerative diseases, including Alzheimer’s disease, Parkinson's disease, Huntington's disease, Multiple sclerosis, and Amyotrophic lateral sclerosis (ALS), with special emphasis on the role of epigenetics, non-coding RNA in neural plasticity as well as pharmacogenomics on treatment response.
We welcome submissions in the form of original research articles, review articles, literature reviews, mini-reviews, systematic reviews, or case studies that cover the following (but are not limited to) topics:
•Novel molecular targets in the diagnosis, pathogenesis, and progression of neurodegenerative diseases, which include:
-Mitochondrial dysfunction
-Endoplasmic reticulum-stress pathways
-Mitotoxicity, oxidative stress, and inflammation
•Epigenetics, including non-coding RNA expression patterns and profiling in neurodegenerative diseases.
•Translational research of nutraceuticals mechanism of action in neurodegenerative diseases.
•Clinical studies using nutraceuticals in neurodegenerative diseases.
•Immunotherapies in neurodegenerative diseases.
•Types of food-based nutraceuticals (Nutrients, minerals, fatty acids, vitamins, and amino acids).
•Probiotics and microbiome-brain crosstalk in neurodegenerative diseases.
•Impact of Polymorphism on progression and response to nutraceuticals in clinical studies.
